Scholars Central

Conference abstractPublished 23 Sep 2013

Biosimilar in pharmerging markets

Authors: Jun Wang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Recently, the expiration of patents for a number of blockbuster biologics in EU and US has ushered in an era of the subsequent production of biosimilar products, which might contribute to increased access to these products at an affordable price. However, biopharma sales in these major markets will grow slowly during the next ten years and global pharmaceutical industry is turning to emerging markets such as China, India, Brazil, and Russia for growth and profitability. This presentation will review the patent protections of some blockbuster biologics in pharmerging markets and the potential advantages and obstacles of developing biosimilars in these emerging market.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Jun Wang”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels